Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.

Health Data Futures project - 11/01/2024

Creating a network of trust

In the three-nation project "Health Data Futures", stakeholders and experts from Germany, France and Switzerland have launched a series of patient-centred innovations. Using various future scenarios, the project partners may be able to come up with even more scenarios.

The family-owned MedTech company KARL STORZ announces the acquisition of the innovative software manufacturer Innersight Labs Ltd. (ISL) headquartered in London. In addition to state-of-the-art endoscopes, high-end medical devices, and integrated solutions for the operating room, KARL STORZ is also continuing to expand in innovative software solutions.

The German Cancer Society has certified the Center for Personalized Medicine (ZPM) at Heidelberg University Hospital. At the ZPM Heidelberg, patients with advanced and rare cancers and, in future, people with severe chronic inflammatory diseases will receive a molecular genetic analysis. The detailed information can open up new treatment options for those affected.

The ‘Photon-Counting’ (PC)-CT consortium received funding in the next round of funding from the Forum Health Region Baden-Württemberg. The aim of the new consortium was to install the image data infrastructure ‘teamplay digital health platform connect’ (tdhp) at four clinical sites for digital exchange in the follow-up project PC3-AIDA.

Dossier - 11/10/2023

The quantum revolution in the healthcare industry

From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.

The demand for skilled workers in Germany is high - especially in the healthcare sector. But the procedure for hiring and recognising qualifications is complex. In Baden-Württemberg, the Welcome Center Sozialwirtschaft Baden-Württemberg is one of the contact points for companies and professionals seeking advice on the process.

A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state.

Expert interview - 28/06/2023

Money isn't all that is needed – knowledge and networking can also help start-ups move forward

Dr. Rolf Neuhaus is one of the driving forces behind PALATINA Business Angels Rhein-Neckar e.V., a business angels association in the Rhine-Neckar metropolitan region. In an interview with BIOPRO, Neuhaus describes the association’s activities and explains where there is still catching up to be done in terms of start-up support in Baden-Württemberg.

Detecting drug resistance of tumour cells - 25/05/2023

AI-assisted diagnostics declares war on lung cancer

Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.

Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

The Phytopharmaceuticals and Valuable Plant Ingredients initiative aims to further develop phytopharmaceuticals and valuable plant ingredients in Baden-Württemberg.

Press release - 31/03/2023

Simulation of Miscanthus- and Sorghum-based resilient value chains in the Danube Region

Can the value chains in the Danube macro-region be more sustainable and resilient against disruptions such as pandemics? How modelling could help to simulate the economic viability of developing Miscanthus and Sorghum based value chains in that region?

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

Non-profit limited liability company creates institutional framework for interdisciplinary research collaboration, innovative technology development and outstanding healthcare in the Rhine-Neckar region.

Photon-counting technology - 01/02/2023

PC3 consortium: innovative computed tomography for Baden-Württemberg

The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.

Press release - 16/01/2023

GoDanuBio’s contribution to the bioeconomisation of the Danube Region

GoDanuBio supported the set-up of policy frameworks and participative governance schemes in the participating regions. The main topics were circular bioeconomy, sustainable rural development and rural-urban interactions.

Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

Press release - 29/11/2022

Five European pilot regions are joining forces for the bioeconomy

BIOPRO Baden-Württemberg participates in the Horizon Europe ROBIN project to improve the participation of regional bioeconomy strategies and related policies across Europe.

Remaining mobile and producing without overtaxing the earth’s natural regenerative capacity: That’s the aim of the Innovation Campus “Mobility of the Future” (ICM) at the Karlsruhe Institute of Technology (KIT) and the University of Stuttgart. Here, in about 60 research projects and 40 research institutes, almost 300 scientists are working on electric motors without rare earths, novel manufacturing technologies, and self-learning software systems…

Mobil bleiben und produzieren, ohne die natürliche Regenerationsfähigkeit der Erde zu überfordern, das ist der Anspruch des InnovationsCampus Mobilität der Zukunft (ICM) am Karlsruher Institut für Technologie und der Universität Stuttgart. Fast 300 Forschende in gut 60 Forschungsprojekten und 40 -instituten arbeiten hier an Elektromotoren ohne Seltene Erden, neuartigen Fertigungstechnologien und selbstlernenden Software-Systemen für Fahrzeuge.

Across the EU, more than 300 billion items of packaging are not recycled every year because they consist of a mixture of different materials. Monomaterial packaging on the other hand is easy to recycle. However, it needs to be coated with ultra-thin barrier layers to protect delicate products just as well as compound materials do.

Press release - 23/09/2022

Phytopharmaceuticals and valuable plant ingredients - opportunities for industry and agriculture in Baden-Württemberg

The "Phytopharmaceuticals and Valuable Plant Ingredients" initiative aims to make the key economic issue of phytopharmaceuticals more visible in Baden-Württemberg in order to gain a better understanding of the challenges and needs of the state’s pharmaceutical industry. The overall goal is to strengthen the use of secondary plant ingredients in valuable products and build on this to develop opportunities for Baden-Württemberg…